Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHA NASDAQ:KROS NASDAQ:OLMA NASDAQ:SIGA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.06+2.5%$2.07$1.29▼$3.51$185.28M0.0421,789 shs13,786 shsKROSKeros Therapeutics$15.94+2.3%$15.09$9.12▼$72.37$632.79M0.97367,226 shs476,037 shsOLMAOlema Pharmaceuticals$11.10-0.4%$6.80$2.86▼$13.51$764.59M2.081.38 million shs787,811 shsSIGASiga Technologies$8.95$8.49$4.95▼$9.62$640.87M0.96502,012 shs422,020 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.61%+10.43%-3.42%+10.37%-7.39%KROSKeros Therapeutics+1.96%-1.39%-0.89%+16.88%-74.59%OLMAOlema Pharmaceuticals+0.91%+36.02%+72.18%+153.18%-7.55%SIGASiga Technologies-3.03%+1.94%+3.71%+32.89%+29.34%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.06+2.5%$2.07$1.29▼$3.51$185.28M0.0421,789 shs13,786 shsKROSKeros Therapeutics$15.94+2.3%$15.09$9.12▼$72.37$632.79M0.97367,226 shs476,037 shsOLMAOlema Pharmaceuticals$11.10-0.4%$6.80$2.86▼$13.51$764.59M2.081.38 million shs787,811 shsSIGASiga Technologies$8.95$8.49$4.95▼$9.62$640.87M0.96502,012 shs422,020 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma+1.61%+10.43%-3.42%+10.37%-7.39%KROSKeros Therapeutics+1.96%-1.39%-0.89%+16.88%-74.59%OLMAOlema Pharmaceuticals+0.91%+36.02%+72.18%+153.18%-7.55%SIGASiga Technologies-3.03%+1.94%+3.71%+32.89%+29.34%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 2.00Hold$6.50215.53% UpsideKROSKeros Therapeutics 2.40Hold$30.0088.21% UpsideOLMAOlema Pharmaceuticals 2.57Moderate Buy$24.00116.22% UpsideSIGASiga Technologies 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest IPHA, SIGA, OLMA, and KROS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025IPHAInnate PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025KROSKeros TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025OLMAOlema PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SIGASiga TechnologiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/18/2025IPHAInnate PharmaLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/18/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/18/2025IPHAInnate PharmaLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$10.00 ➝ $2.009/9/2025OLMAOlema PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/3/2025OLMAOlema PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/14/2025OLMAOlema PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$28.00 ➝ $29.008/12/2025OLMAOlema PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $21.00(Data available from 10/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$21.77M8.72N/AN/A$0.11 per share18.73KROSKeros Therapeutics$3.55M182.39N/AN/A$14.11 per share1.13OLMAOlema PharmaceuticalsN/AN/AN/AN/A$7.14 per shareN/ASIGASiga Technologies$138.72M4.62$0.84 per share10.69$3.02 per share2.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/AN/AKROSKeros Therapeutics-$187.35M$0.3151.42N/A2.018.06%2.96%2.74%11/5/2025 (Estimated)OLMAOlema Pharmaceuticals-$129.47M-$1.98N/AN/AN/AN/A-42.58%-38.65%11/11/2025 (Estimated)SIGASiga Technologies$59.21M$1.137.927.16N/A45.73%40.52%35.62%11/6/2025 (Estimated)Latest IPHA, SIGA, OLMA, and KROS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025OLMAOlema Pharmaceuticals-$0.43-$0.51-$0.08-$0.51N/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 million8/5/2025Q2 2025SIGASiga TechnologiesN/A$0.49N/A$0.49N/A$81.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AOLMAOlema PharmaceuticalsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate Pharma3.522.21N/AKROSKeros TherapeuticsN/A21.1121.11OLMAOlema Pharmaceuticals0.0111.0911.09SIGASiga TechnologiesN/A10.098.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%KROSKeros Therapeutics71.56%OLMAOlema Pharmaceuticals91.78%SIGASiga Technologies55.40%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%KROSKeros Therapeutics20.60%OLMAOlema Pharmaceuticals16.36%SIGASiga Technologies1.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableOLMAOlema Pharmaceuticals7068.63 million57.41 millionOptionableSIGASiga Technologies4071.61 million70.21 millionOptionableIPHA, SIGA, OLMA, and KROS HeadlinesRecent News About These CompaniesInvestors Purchase Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)October 2 at 2:37 AM | marketbeat.comGoldman Sachs Group Inc. Decreases Holdings in Siga Technologies Inc. $SIGASeptember 20, 2025 | marketbeat.comHarbor Capital Advisors Inc. Reduces Holdings in Siga Technologies Inc. $SIGASeptember 19, 2025 | marketbeat.comInvestors Buy Large Volume of Siga Technologies Call Options (NASDAQ:SIGA)September 18, 2025 | marketbeat.comHealthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse...September 11, 2025 | marketbeat.comTraders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)September 5, 2025 | marketbeat.comNuveen LLC Makes New $815,000 Investment in Siga Technologies Inc. $SIGASeptember 4, 2025 | marketbeat.comSIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA NewsAugust 20, 2025 | seekingalpha.comSIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)August 8, 2025 | finance.yahoo.comSIGA (SIGA) Q2 Revenue Soars 272%August 7, 2025 | theglobeandmail.comSIGA Technologies (SIGA) Reports Significant Earnings DeclineAugust 6, 2025 | finance.yahoo.comSIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA fundingAugust 6, 2025 | msn.comSIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comSIGA Reports Financial Results for Three and Six Months Ended June 30, 2025August 5, 2025 | globenewswire.comSIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 ResultsJuly 29, 2025 | globenewswire.comSiga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to KnowJuly 24, 2025 | zacks.comSiga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should KnowJuly 15, 2025 | msn.comUS Market's Undiscovered Gems Featuring Three Promising Small CapsJuly 15, 2025 | finance.yahoo.comSiga Technologies Inc. (SIGA) Laps the Stock Market: Here's WhyJuly 9, 2025 | zacks.comSIGA Technologies Inc Dividends - MorningstarJuly 8, 2025 | morningstar.comMWhy Siga Technologies Inc. (SIGA) Outpaced the Stock Market TodayJune 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPHA, SIGA, OLMA, and KROS Company DescriptionsInnate Pharma NASDAQ:IPHA$2.02 +0.01 (+0.55%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Keros Therapeutics NASDAQ:KROS$15.94 +0.36 (+2.31%) Closing price 04:00 PM EasternExtended Trading$15.94 0.00 (0.00%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Olema Pharmaceuticals NASDAQ:OLMA$11.10 -0.04 (-0.36%) Closing price 04:00 PM EasternExtended Trading$11.31 +0.21 (+1.89%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Siga Technologies NASDAQ:SIGA$8.95 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$9.08 +0.13 (+1.45%) As of 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
